Adial Pharmaceuticals is dedicated to finding medicinal solutions for Alcohol Use Disorder (AUD). As a part of our efforts, we are conducting a survey to better understand the habits and issues surrounding the use of alcohol and need your help. No identification information will be collected, so your response will be anonymous.
Genetically Targeted
Designed to reduce craving to effectively curb alcohol intake in those patients with the genetics expected to indicate a likely response to treatment with AD04
BRINGS 20+ YEAR TRACK RECORD OF CLINICAL USE
To date, clinical testing of AD04 has shown it to have a positive safety and tolerability profile with side effects similar to placebo.
Oral daily dosing
Our product candidate is intended to be easy to use since it is administered orally.
Media
AUD is characterized by an urge to consume alcohol and an inability to control the levels of consumption
Email Alerts
SIGN UP TODAYLatest Tweets
Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder https://t.co/O52nt5L5D2
Adial in home stretch of anti-alcohol abuse drug trials
https://t.co/SG31eYuMLu
Watch Adial's CEO @BillStilley featured #live on @cheddar's Closing Bell
@CheddarNews #opioidcrisis #opioid #addiction #drugaddiction
https://t.co/3apirUTU4G
AD04 Ready to Enter Phase 3 in Targeted Groups
Adial is preparing to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.
Adial has created an investigational attendant diagnostic biomarker blood test for the genetic screening of patients with certain biomarkers that, as reported in the American Journal of Psychiatry (Johnson, et. al. 2011 & 2013), Adial believes make patients more likely to benefit from treatment with AD04.
Adial’s strategy is to integrate pre-treatment genetic screening into AD04’s label to create a patient-specific treatment in one integrated therapeutic offering. Adial’s goal is to develop a genetically targeted, effective and safe product candidate to treat AUD that does not require abstinence as part of the treatment.